ViiV Healthcare announced the start of a Phase III clinical trial programme to evaluate the safety and efficacy of dolutegravir ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

GlaxoSmithKline (GSK) Reports Q1 EPS of 167p; Will Retain Stake in ViiV HealthcareMay 6, 2015 7:42 AM ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance TherapyMay 6, 2015 4:54 AM